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Abstract 
 
 
The ability to directly detect tau protein and other neurodegenerative biomarkers in human 
plasma at clinically relevant concentrations continues to be a significant hurdle for the 
HVWDEOLVKPHQWRIGLDJQRVWLFWHVWVIRU$O]KHLPHU¶VGLVHDVH$',QWKLVDUWLFOHZHLQWURGXFHD
new DNA aptamer/antibody sandwich assay pairing and apply it for the detection of human 
Tau 381 in undiluted plasma at concentrations as low as 10 fM. This was achieved on a multi-
channel surface plasmon resonance (SPR) platform with the challenge of working in plasma 
overcome through the development of a tailored mixed monolayer surface chemistry. In 
addition, a robust methodology was developed involving various same chip control 
measurements on reference channels to which the detection signal was normalized.  
Comparative measurements in plasma between SPR and enzyme-linked immunosorbent assay 
(ELISA) measurements were also performed to highlight both the 1000-fold performance 
enhancement of SPR and the ability to measure both spiked and native concentrations that are 
not achievable with ELISA. 
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Introduction 
The establishment and sensitive detection of blood biomarkers that can be used as a reliable 
DSSURDFKIRUWKHVFUHHQLQJRIQHXURGHJHQHUDWLYHFRQGLWLRQVVXFKDV$O]KHLPHU¶VGLVHDVH$'
in a clinical setting continues to be a major challenge.1,2 Currently, the cost and time involved 
in diagnosing AD and other neurodegenerative conditions remains a major hurdle in tackling a 
condition which is rapidly increasing in priority for society.3 Efforts by researchers are 
hampered by a lack of accurate and sensitive analytical techniques capable of molecular-
specific measurements in blood samples along with the growing need to compare the levels of 
different biomarker populations simultaneously. Amyloid-E peptides and Tau proteins are 
consistently reported as promising serum biomarker candidates for AD patients along with a 
range of peripheral marker candidates connected to immunological mechanisms, inflammation 
and oxidative stress, and protein signaling pathways are also of interest.4-6 In the case of Tau 
protein, increased levels in AD patient plasma has been reported,7 however varying overlap in 
concentrations between different patient categories has prevented a plasma-based clinical 
screening tool being established. 
 
Despite the limitations of the conventional enzyme-linked immunosorbent assay (ELISA) 
format,8,9 there have been very few alternative approaches reported capable of the rapid and 
direct detection of Tau in plasma. Recently, a single molecule ELISA digital array technology10 
has been applied to the detection of femotmolar levels of Tau in blood. Surface plasmon 
resonance (SPR) has also been used to quantify the interaction between different Tau forms 
and antibodies11,12 as well as study DNA-Tau interactions,13 however no SPR measurements in 
plasma have been reported. Nanoparticles have been applied to create a localized SPR14 sensor 
as well as surface-enhanced Raman scattering15 and multi-photon scattering16 platforms but 
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these studies were demonstrated in buffer only. Furthermore, all Tau diagnostic measurements 
reported to date have been limited to the use of either a single monoclonal antibody or an 
antibody pair in a sandwich assay format. Thus, the integration of nucleic acid aptamers17,18 as 
an alternative alongside robust platforms capable of multiplexed bioaffinity measurements 
would potentially have a major impact on AD research. 
 
In this article, we report a new DNA aptamer/antibody pairing specific to Tau protein (Tau-381 
isoform) for the first time and apply this assay on a multi-channel SPR platform for the direct 
detection of Tau in human plasma at femtomolar concentrations. Despite SPR now being a 
well-established technique for bioaffinity sensing,19-23 the quantitative detection of target 
proteins in plasma has proved challenging and among the recent examples published24,25 an 
even fewer number report analysis in plasma without significant dilution in buffer prior to 
measurement.26 Recently, we reported a new sandwich assay for another potential biomarker 
for AD, Į-1 antitrypsin (AAT).27 As the native concentration of AAT is ~40 PM, these 
measurements involved significant serum dilution in buffer prior to analysis. However, such 
an approach is not feasible for protein targets like Tau where concentrations in healthy patients 
can be in the femtomolar range.7 Thus, after establishing the DNA aptamer/Tau 381/antiTau 
sandwich assay performance in buffer, we also describe a robust methodology for the 
quantitative detection of Tau in plasma at clinically relevant concentrations. To achieve this, 
various mixed monolayer surface chemistries were compared in the optimization of the SPR 
chip as well as a series of non-specific controls simultaneously acquired on the same chips. 
Conventional ELISA measurements were also performed to support our results. 
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Experimental Section 
More extensive information on the materials used and the protocols related to SPR chip 
preparation, protein detection and also ELISA measurements are provided in the Supporting 
Information. In short, all in-situ SPR bioaffinity measurements were performed using a Biacore 
3000. Recombinant Human Tau 381 full length protein (Tau) and tau antibody (antiTau) were 
acquired from Abcam. A 5'-amine modified DNA aptamer28 specific to Tau, whose sequence 
is 5'-H2N-GCGGAGCGTGGCAGG-3' was purchased from IDT along with a control sequence, 
NC4, 5'-H2N-AGTACAAGAAGCTTACCAGCGAACTCAGTAGT CTGATATATATAACC-
3' which is actually specific to platelet factor 4.29 The proteins used for control measurements 
were recombinant human complement (CFH, R&D Systems) and human complement factor H 
antibody (antiCFH, R&D Systems). ELISA measurements were performed using a RayBio® 
human Tau ELISA kit (RayBiotech) featuring a 96 well microplate pretreated with antiTau in 
conjunction with a Sunrise-basic microplate absorbance reader (Tecan). For ELISA 
measurements, two different Tau proteins were used for the kit performance comparison; (i) 
Tau 381 human utilized in the SPR and (ii) Tau protein provided by the ELISA kit were used 
for ELISA measurements. All biomolecular interaction measurements were either performed 
in solution 1x PBS buffer pH 7.4 (Life Technologies) only, or directly in plasma from human 
(Sigma-Aldrich). When performing spiked measurements, different ȝ/ aliquots of the Tau 
stock concentration (10 pM) of tau was directly added to plasma (2-3 mL) to prepare the desired 
spiked tau concentration. 
 
Results and Discussion 
SPR Detection of Tau Protein: It has been shown that Tau can bind to single-stranded DNA 
(ssDNA)28 and double-stranded DNA (dsDNA).13 Indeed, it is understood that Tau protein 
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plays a significant role in the protection of neuronal nucleic acids and that a combination of 
Tau deficiency and alterations (e.g. hyperphosphorylation) contributes to the DNA and RNA 
R[LGDWLRQGDPDJHREVHUYHGLQ$O]KHLPHU¶V30 However, while there have been several studies 
on Tau interactions with DNA sequences featuring several hundred bases, we found only one 
previous study demonstrating Tau affinity for a short DNA sequence,28 which, to our 
knowledge, has never been subsequently developed as an aptamer candidate for affinity-based 
sensing. Here, we demonstrate a previously unreported aptamer-antibody pairing for specific 
Tau detection.   
 
Figure 1. Schematic overview of strategy for Tau protein detection. Mixed monolayers of MUA and 
MUD were first immobilized on a SPR chip followed by the covalent attachment of DNA aptamer probes. 
Specific adsorption of Tau proteins was monitored in both buffer and plasma followed by the subsequent 
binding of antiTau. Images representative of Tau and CFH proteins are reproduced from references 
31and 32, respectively. 
 
An overview of the sandwich assay developed for plasma based detection is provided in Fig. 
1. The SPR gold chip was first modified with a mixed monolayer of 11-mercaptoundecanoic 
acid (MUA) and 11-mercaptoundecanol (MUD).33 Both the Tau specific DNA aptamer and 
control sequences were covalently coupled to MUA via a 5' end NH2 modification and 
EDC/NHSS linking chemistry. Tau specific adsorption measurements were first performed in 
buffer to establish the binding affinity of the DNA aptamer before progressing to measurements 
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in plasma. Further enhancement of the SPR detection signal is then achieved by subsequently 
flowing antiTau (suspended in buffer) across the chip surface resulting in the formation of the 
surface sandwich complex. The covalent coupling of the DNA aptamer to the SPR chip surface 
is preferred to antibody coupling when there is a choice between both options. This is due to 
the better control over the probe molecule surface attachment, packing densities and non-
specific adsorption behavior that can be achieved using aptamer functionalization compared to 
antibody probes.27,34 
  
Tau 381 is one of six known variants ranging from 352 to 441 amino acids in length.35 The 
relative abundance and molecular mechanism of each variant is still poorly understood and 
commercially available ELISA kits do not differentiate between variants, suggesting common 
epitope sites for antibody pairs across all species. For our investigation, we focused on tau 381 
(Tau) based on the original study of Tau ± ssDNA interactions by Krylova et al28 who also 
reported similar interaction behavior for the Tau 410 isoform. An initial assessment of the DNA 
aptamer ± Tau interaction was first performed with the aptamer attached to a chip surface 
featuring only MUA rather than a mixed monolayer. A series of SPR measurements were 
performed monitoring Tau specific adsorption in buffer with the resulting change in reflectivity 
units (' R.U.) obtained at different target concentrations plotted in Fig. 2a. This data was then 
used to create a plot of fractional surface coverage (T ) versus concentration, which was then 
fitted with a Langmuir adsorption isotherm model to obtain an adsorption coefficient (Kads) 
value of 6.3 (±0.1) × 108 M-1. Comparative measurements were also performed using an 
antiTau modified SPR chip instead of the aptamer, which revealed a significantly lower Kads of 
4.0 (±0.3) × 107 M-1 (see Fig. S1 and Fig. S2 in the supporting information). This confirms the 
high affinity of the aptamer sequence for the Tau protein target and is at least comparable to 
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other aptamer-protein interactions reported recently by us e.g. Kads = 2.0 (±0.2) × 108 M-1 for 
IgE protein-DNA aptamer36 and Kads = 4.8 (±0.1) × 108 M-1 for AAT protein-DNA aptamer 
affinity interactions.27  
 
The utilization of mixed MUA:MUD monolayers was then explored. The motivation for this 
is based on recent reports that this approach promotes reduced non-specific adsorption of 
proteins,37 plus DNA, peptide33 which is important for successful measurements in biofluids. 
A systematic study of the SPR sensing performance and also non-specific binding of bovine 
serum on mixed MUA:MUD layers has also been reported by Booksh et al,38 which highlighted 
the improvements that can be achieved using MUD. Shown in Fig. 2a are data series acquired 
for SPR chips prepared by initially incubating the bare gold surfaces with different molecular 
ratios of MUA and MUD prior to coupling the aptamer probe. As expected, smaller signals are 
observed when the surface density of the immobilized aptamer is lowered. For the 40% MUD 
monolayer, the measured signal is only slightly lower than that obtained at 100% MUA 
coverage. A plot of fractional surface versus concentration is also shown in Fig. 2b alongside 
the results from an experiment where 40% MUD was instead replaced with 40% PEG-SH. For 
comparative purposes, the largest signal change associated with the 100% MUA measurements 
was utilized to calculate the fractional surface coverage of Tau at each monolayer composition. 
It can be clearly seen that a much lower signal is obtained for the 40% PEG monolayer than 
for 40% MUD, indicating that a better detection performance is obtained with the latter. The 
Langmuir isotherm fitting of the 100% MUA chip is discussed above and the fitting of the 40% 
MUD, 60% MUD and 40% PEG chips are shown in the supporting info, Fig. S2. A poorer fit 
quality was observed for the 40% PEG containing layer compared to all the MUA/MUD mixed 
layers tested as well as the 100% MUA layer. Representative SPR detection and non-specific 
9 
 
control plots for both the MUD and PEG mixed monolayers are also shown in the supporting 
information where similar responses are observed. The poorer performance of the PEG layer 
observed throughout this work may thus be associated more with the organization of the mixed 
monolayer and the availability of the MUA end group for covalent coupling to the aptamer 
probe, with the PEG-SH being both longer and a different hydrophobicity than the MUD 
alkanethiol. 
 
 
Figure 2. (a) Change in SPR signal obtained upon flowing a series of Tau concentrations in PBS buffer 
are compared for chip surfaces prepared with 100% MUA and at MUA:MUD ratios of 60:40, 40:60 
and 20:80. (b) Comparison of Langmuir adsorption isotherm plots showing fractional surface coverage 
(T) versus Tau protein concentration for SPR chip surfaces with monolayers featuring 100% MUA, 60% 
MUA:40% MUD and 60% MUA:40% PEG. In all three curves, the maximum signal change associated 
with the 100% MUA surface is used for normalization.  
 
Sandwich Assay: The formation of the surface sandwich assay was also first investigated in 
buffer solution using SPR chips prepared with different mixed monolayer compositions. Figure 
3 compares a series of plots where antiTau is flowed across different SPR chips prepared with 
MUA:MUD ratios varying from 100:0 to 40:60 alongside a MUA:PEG ratio of 60:40. For each 
data point, the chip concerned was systematically exposed to a Tau concentration in the 
femtomolar range for at least one hour before injecting antiTau, which was kept at a fixed 
concentration of 100 nM. We have previously shown that the SPR response range and signal 
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amplification also depends on the secondary probe concentration.27,39 The utilization of 100 
nM antiTau in Fig. 3 is based on a series of measurements shown in Fig. S4 in the supporting 
information where different combinations of monolayer composition and antiTau 
concentrations are compared at a fixed Tau concentration. The results in both Figs. S3 and S4 
indicate that the measurement dynamic range can be controlled via both the MUA:MUD ratio 
and the antiTau concentration with no significant improvement in sensing performance at 
antiTau concentrations above 100 nM. Importantly, these results also clearly confirm that the 
DNA aptamer and antiTau bind simultaneously to the Tau protein target via different epitope 
sites. 
 
 
Figure 3.  Normalized 'R.U. SPR responses monitoring the specific binding of antiTau onto chip 
surfaces that have been initially prepared with different MUA:MUD ratios (100:0 to 40:60) as well as 
MUA:PEG ratio of 40:60. Following attachment of the aptamer probe, each chip design was exposed 
to a different femtomolar concentration of Tau in PBS buffer, which was then followed by antiTau at a 
fixed concentration of 100 nM. The linear response range in each data series is highlighted by the 
dotted line.  
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The normalized 'R.U. values shown in Fig. 3 were obtained by acquiring the average 'R.U. 
signals associated with specific target binding and subtracting this from an average of the non-
specific control signals, NC1 to NC4. These are summarized in Table 1, and involve repeat 
measurements in the absence of Tau (NC1), using a different target protein (CFH, NC2), 
replacing antiTau with anti-CFH (NC3) or instead using a different aptamer sequence (NC4). 
For every data point presented in Fig. 3, control measurements were acquired utilizing two of 
the available 4 SPR chip channels with different controls used over the course of three repeat 
measurements to obtain an average signal. Representative NC measurements in buffer at 
different monolayer compositions are shown in Fig. S5 in the supporting information. In each 
case the NC SPR response is consistently much smaller than that of the measurements shown 
in Fig. S6. The fact that no consistent correlation in the relative intensities of control signals at 
different monolayer compositions was observed was another reason to use an average of the 
NC responses for normalization. We have found this methodology involving a series of 
simultaneous control measurements to be a robust approach to quantify the specific adsorption 
of the secondary antibody probe onto chip surfaces, especially where the target protein is 
present at low fractional surface coverages associated with femtomolar target concentrations.   
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 NC1 NC2 NC3 NC4 
Aptamer Tau sequence 
Control 
sequence 
Protein None CFH Tau 
Antibody AntiTau AntiCFH AntiTau 
Scheme 
    
Table 1. Summary of negative control measurements used in reference SPR chip channels to which the 
Tau detection channel signals are normalized with respect to during the antiTau binding step performed 
in buffer. 
 
Measurements in Plasma: Having established the Tau assay in buffer for different mixed 
monolayer compositions we then performed a series of SPR measurements directly in plasma 
alongside comparative measurements using a commercial ELISA sandwich assay kit and plate 
reader. Based on the optimization measurements described above, the antiTau concentration 
for the SPR sandwich assay was fixed at 100 nM to enable femtomolar detection levels since 
the Tau concentration in normal patient plasma samples has been recently reported as low as 
60-170 fM, respectively.7 The measurement dynamic range was further tuned by utilizing either 
60% MUA:40% MUD or 40% MUA:60% MUD or 60% MUA:40% PEG monolayer surfaces.  
 
Figure 4 shows a series of SPR results for different concentrations of Tau spiked into undiluted 
plasma for each of the three different monolayer compositions. Representative real-time RU 
plots are shown for spiked, non-spiked and negative control (NC) measurements along with 
the corresponding 'R.U. and normalized 'R.U. plots obtained for each data series. From the 
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R.U. plots (Figs. 4a, 4d, 4g) it can be seen that both the spiked and non-spiked data curves are 
both consistently higher than the negative control data curves (see Fig. S7 for additional 
comparative plots). As expected, the R.U. signals for Tau-spiked plasma were consistently 
higher than the equivalent measurements performed in buffer. In order to clearly demonstrate 
the relative contributions of both non-specific adsorption of plasma proteins and also the 
specific adsorption of Tau to the larger signal, both 'R.U. (Figs. 4b, 4e, 4h) and normalized 
'R.U. (Figs. 4c, 4f, 4i) plots were calculated. The results of linear fitting both are shown in 
Table S1 (supporting information) alongside the same analysis for the equivalent measurements 
performed in buffer earlier. The slope values for both the 60% MUA:40% MUD and 40% 
MUA:60% MUD spiking data sets show agreement between the plasma and buffer 
measurements. This indicates that the increase in the raw R.U. signal associated with non-
specific adsorption is generally uniform across all measurements and that the relative increases 
in signal between data points is due to a higher spiked Tau concentration. However, the 60% 
MUA:40% PEG monolayer (Figs. 4g, h, i) exhibited a more limited concentration range where 
a linear response was observed. There was also a significant difference in the linear slope fits 
between the plasma and buffer data series for PEG (see Table S1, supporting information) as 
well as poorer SPR signal reproducibility, further highlighting the better performance of MUD 
compared to PEG. This is maybe due to the fact that the tightly and uniformly packed self-
assembled monolayer of MUD mixed with MUA blocks nonspecific adsorption sites on the 
gold surface more effectively without impeding specific interactions.31,35 
 
An estimation of the native Tau concentration initially present in the plasma was obtained by 
analyzing the 'R.U. and normalized 'R.U. plots. Considering the poor performance of the 
PEG containing layer, we focused on the MUA/MUD mixed monolayer chips here. For the 
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'R.U. plots (Figs. 4b, e) the fixed y-offset value between the buffer and plasma series is due 
to a combination of both the presence of Tau alongside non-specific adsorption, while for the 
normalized R.U. plots (Figs. 4c, f) the offset between the two slopes in each case is primarily 
due to Tau specific adsorption. Also shown on all plots in Fig. 4 are measurements obtained 
for plasma only. These data points were compared with the analysis of the spiked Tau data 
series thus providing two approaches for evaluating the relative contribution of Tau specific 
adsorption to the overall SPR response signal. For the 60% MUA chip, utilization of the linear 
slope fit for the normalized 'R.U. series resulted in calculated native Tau concentrations of 50 
fM (from spiked series analysis) and 35 fM (from non-spiked plasma signal). Similarly for the 
40% MUA chip, estimated values of 54 fM and 52 fM were obtained from the spiked and non-
spiked data respectively (see Supporting info for more details). The good agreement between 
each of the data sets provides strong evidence of a native Tau concentration of ~50 fM. This 
value is comparable with the only previous report that we are aware of that utilizes a sensitive 
analytical technique capable of demonstrating low femtomolar concentration levels of the 
target tau protein present in the plasma of healthy patients.7 In addition, it is interesting to note 
that for the 60% MUA chip, ~45% of the SPR response was associated with Tau specific 
adsorption compared to ~57% for the 40% MUA chip. Along with changes in surface probe 
density, this also contributes to the differences in the linear response range and SPR signal 
offsets observed between the two chips. 
 
A final set of Tau detection measurements in both buffer and plasma were performed using a 
commercial ELISA kit and compared with the SPR surface sandwich assay. The ELISA results 
are shown in the supporting information (Fig. S8). A linear response detection range was 
obtained for spiked concentrations ranging from 2 pM to 80 pM in both buffer and plasma 
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solutions with very close overlap in sensing performance in both environments. However, the 
ELISA performance was not sensitive enough to detect Tau present in non-spiked plasma. 
Further calibration assays were also performed comparing the use of the Tau provided by the 
ELISA kit manufacturer or instead using the same Tau 381 utilized in the SPR measurements. 
Interestingly, a steeper response slope was obtained for the Tau solution provided with the 
ELISA kit but no significant signal was detected below 2 pM in either case. These 
measurements highlight the limited sensing performance of ELISA while SPR can be 
successfully applied to perform plasma diagnostics of native biomarker concentrations in the 
low femtomolar region. The improved performance of SPR compared to ELISA is associated 
with combination of several factors including better control over surface chemistry and non-
specific adsorption on the SPR chip and the use of continuous flow microfluidics beneficial at 
low target concentrations rather than static wells. A secondary binding step involving the 
formation of the sandwich assay is required to achieve SPR sensitivities in the fM range and 
the fact that this can be achieved directly for SPR while avoiding the larger errors associated 
with the enzymatic amplification reaction needed for ELISA signal transduction is also a 
significant advantage.  
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Figure 4. Analysis of SPR measurements in plasma for three different chip monolayer compositions: 
60% MUA:40% MUD, 40% MUA:60% MUD, 60% MUA:40% PEG monolayer. (a), (d), (g) Real-time 
SPR measurements of antiTau adsorption following exposure to different Tau concentrations spiked 
directly into plasma, P. (b), (e), (h) 'R.U plots obtained by calculating difference in R.U. signals in 
buffer before and after plasma exposure. (c), (f), (i) is where the 'R.U signal has been normalized with 
respect to the average 'R.U. signal of all NC controls. The filled data point marker in the 'R.U and 
normalized 'R.U. plots represents the plasma signal with no spiking. Representative NC3 and NC4 
plots are also shown in (a), (d) and (g). 
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Conclusions 
In this article, a novel DNA aptamer-antibody sandwich assay specific to Tau protein 
biomarker has been developed and successfully applied for femtomolar concentration analysis 
in human plasma using surface plasmon resonance. The SPR chip surface chemistry was 
optimized via a series of experiments utilizing different ratios of a mixed monolayer of two 
differently terminated alkanethiols followed by the covalent coupling of the DNA aptamer in 
order to reduce the level of non-specific interactions while maintaining the analytical 
performance of the proposed surface sandwich assay. Robust control over the surface chemistry 
in combination with multi-channel measurement capability for simultaneous control 
measurements is essential for measurements in biological fluids such as plasma.  Also, 
comparative measurements using ELISA for Tau analysis in plasma highlighted that the SPR 
based sandwich assay is a more sensitive option. As more important disease biomarkers are 
discovered and the corresponding nucleic acid aptamers selected, it is envisioned that the use 
of multiplexed SPR will continue to become more prevalent for medical diagnostics in 
biofluids. 
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